TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06608615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Facilitation (Functional) Technique for Tibialis Anterior Muscle: The patient sits with his leg extended. The ankle is placed in eversion and dorsi flexion. After one end of the I tape is adhered to the upper part of the Tibia, the other end is adhered to the dorsal surface of the foot with almost 100% tension. During the application, origin and insertion points are considered as the beginning and end. Then, plantar fexion is performed on the ankle and the remaining non-stick part is glued.~Functional Correction Technique: Correction technique is used to ensure full contact of the foot with the ground. The subtalar joint is positioned in eversion and taping is applied starting from under the medial malleolus, without tension until the lateral outer edge of the calceneus, and then with 100% tension, continuing until 10-15 cm below the head of the fibula. No tension is applied in the last 5 cm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Taping
Description: Talus Stabilization Taping: The affected ankle of the person to be taped was placed on a chair and asked to bring this foot to a neutral position by advancing the tibia over the foot through knee flexion while standing. Starting from the talus of the ankle, maximum tension was applied towards the medial and lateral malleolus.~Inversion Lock: This lock looks like an inverted 6 when viewed from the front and is used to restrict inversion movement. After the underwrap and anchor were applied, the tape was applied starting from the outer malleolus level. It was glued on itself by proceeding diagonally in front of the foot, passing it in front of the inner malleolus, passing under the foot and in front of the outer malleolus and closing the subtalar area, and the taping was completed by making an anchor on the upper side.
Study: NCT06607783

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: TBC
Study: NCT06608420

Intervention type: OTHER
Intervention: Gradient Boosting Survival Analysis (GBSA),
Description: It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.

Intervention type: OTHER
Intervention: Concordance index
Description: The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.
Study: NCT06606015

Intervention type: DRUG
Intervention: I.V Paracetamol.
Description: Pharmacological thereby for hsPDA closure in the preterm neonates.

Intervention type: DRUG
Intervention: I.V Paracetamol.
Description: Pharmacological thereby for hsPDA closure in the preterm neonates.

Intervention type: DEVICE
Intervention: Echocardiography.
Description: It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.

Intervention type: DEVICE
Intervention: Echocardiography.
Description: It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.

Intervention type: DEVICE
Intervention: Electrical Cardiometry
Description: Non invasive hemodynamics monitoring

Intervention type: DEVICE
Intervention: Electrical Cardiometry
Description: Non invasive hemodynamics monitoring
Study: NCT05890170

Intervention type: OTHER
Intervention: Patient Reported Outcomes Measures
Description: Questionnaires and information extracted from the medical records would be collected.

Intervention type: OTHER
Intervention: Patient Reported Outcomes Measures
Description: Questionnaires and information extracted from the medical records would be collected.

Intervention type: OTHER
Intervention: Patient Reported Outcomes Measures
Description: Questionnaires and information extracted from the medical records would be collected.
Study: NCT05772663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized program of rehabilitation
Description: D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine program of rehabilitation
Description: Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands.
Study: NCT05694312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Description: Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
Study: NCT04449146

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scapular positioning in Standing position using Sonography
Description: The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
Study: NCT06280872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological Based Cord Clamping
Description: see Arm Description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Differed Cord Clamping
Description: see Arm Description
Study: NCT04900220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
Study: NCT06347614

Intervention type: PROCEDURE
Intervention: Two-step Radical Prostatectomy
Description: The first step was the enucleation of the hyperplastic adenoma, followed by the anterograde radical prostatectomy of residual tissue
Study: NCT04542772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Rehabilitation
Description: Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Rehabilitation
Description: Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
Study: NCT05712616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strontium Ranelate
Description: Dual mode of action, anabolic and anti-resorptive

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lacto-N-Hexaose
Description: Placebo look alike drug
Study: NCT06121687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shaeer-I
Description: Ligation of the internal pudendal vein under the Gluteus Maximus muscle as it courses above the scar-spinous ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPI
Description: Penile prosthesis implantation (PPI) will be performed
Study: NCT06140940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current (HD-tDCS), active condition
Description: Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
Study: NCT05945043

Intervention type: OTHER
Intervention: Surface parasternal eletromyogram
Description: The surface parasternal EMG of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
Study: NCT06140940

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High-definition transcranial direct current (HD-tDCS), sham condition
Description: Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
Study: NCT05945043

Intervention type: OTHER
Intervention: Surface diaphragm electromyogram
Description: The ipsilateral and contralateral surface diaphragm EMG of participants will be measured pre and immediately post pleural fluid removal

Intervention type: OTHER
Intervention: Parasternal muscle ultrasound
Description: The thickness of the parasternal intercostal muscle of participants will be measured using thoracic ultrasound pre and immediately post pleural fluid removal

Intervention type: OTHER
Intervention: Breathlessness assessment
Description: The VAS breathlessness score and Dyspnoea-12 questionnaire of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
Study: NCT06239376

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa+AI - AC
Description: Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial cycle
Description: The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises estradiol 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
Study: NCT05725109

Intervention type: OTHER
Intervention: Hepatitis C Treatment Alerts in CHORUS™
Description: Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based healthcare analytics and reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients with certain conditions who have a scheduled appointment in the coming week and may require close attention. CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. In the after period of this study, the alert will identify patients with active hepatitis C infection.

Intervention type: OTHER
Intervention: Standard of Care
Description: CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients with active hepatitis C infection will be disseminated.
Study: NCT05735132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Line-blocking
Description: Participants will receive a 2 cm subcutaneous 1% lidocaine local infiltration injection parallel to the arm at the puncture site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bar-blocking
Description: Participants will receive a bar-shaped subcutaneous 1% lidocaine local infiltration injection in the vertical arm, 2 cm away from the puncture site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V-blocking
Description: Participants will receive a V-shaped subcutaneous 1% lidocaine local infiltration injection at a 90-degree angle 2 cm away from the puncture site.
Study: NCT05048940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Janssen vaccine
Description: 0.5 ml millilitre(s) Intramuscular use

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (Moderna) vaccine
Description: 0.5 ml millilitre(s) Intramuscular use
Study: NCT04474704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheetah® non-invasive cardiac monitoring system
Description: Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: 24 hours of postpartum magnesium sulfate
Study: NCT04887051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonory based home exercises
Description: web based telerehablitation
Study: NCT04811625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PL-ASA
Description: Pharmacologic profile of different aspirin formulations

Intervention type: DRUG
Group type: OTHER
Intervention: PL-ASA
Description: Pharmacologic profile of different aspirin formulations
Study: NCT05209438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset Research
Description: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cereset Research
Description: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study: NCT04899921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous injection
Study: NCT05040152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling and Surveillance
Description: Receive dietary recommendations
Study: NCT04899921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous injection
Study: NCT05040152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete home exercises
Study: NCT04899921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenously (IV) into the vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenously (IV) into the vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenously (IV) into the vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenously (IV) into the vein
Study: NCT06162546

Intervention type: OTHER
Intervention: Registry
Description: Registry Participation, providing data and clinical specimen
Study: NCT06195969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: automated instant message-guided hypertension management intervention group
Description: Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al., we will develop a message content library and protocol for EMI delivery
Study: NCT04899921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenously (IV) into the vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Taken orally
Study: NCT05040152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive education brochures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04899921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taken orally
Study: NCT05797038

Intervention type: DRUG
Intervention: Tacrolimus for the treatment of IMN
Description: Remission after tacrolimus treatment of IMN

Intervention type: DRUG
Intervention: Tacrolimus for the treatment of IMN
Description: Remission after tacrolimus treatment of IMN
Study: NCT05682287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 448kHz capacitive resistive monopolar radiofrequency
Description: Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
Study: NCT06140381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric training
Description: The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: 3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: 3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
Study: NCT05426031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protamine fixed dose
Description: 250 mg of protamine intravenously (IV), one time use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine ratio dose
Description: 1mg of protamine per 100 units of heparin given intravenously (IV), one time use